RPL9 acts as an oncogene by shuttling miRNAs through exosomes in human hepatocellular carcinoma cells

Li,Ang; Li,Ang; Li,Ang; Li,Ang; Li,Ang; Li,Ang; Li,Ang; Li,Ang; Li,Ang; Li,Ang; Li,Ang; Li,Ang; Xie,Jiyan; Xie,Jiyan; Xie,Jiyan; Xie,Jiyan; Xie,Jiyan; Xie,Jiyan; Xie,Jiyan; Xie,Jiyan; Xie,Jiyan; Xie,Jiyan; Xie,Jiyan; Xie,Jiyan; Lv,Lihong; Lv,Lihong; Lv,Lihong; Lv,Lihong; Lv,Lihong; Lv,Lihong; Lv,Lihong; Lv,Lihong; Lv,Lihong; Lv,Lihong; Lv,Lihong; Lv,Lihong; Zheng,Zhihua; Zheng,Zhihua; Zheng,Zhihua; Zheng,Zhihua; Zheng,Zhihua; Zheng,Zhihua; Zheng,Zhihua; Zheng,Zhihua; Zheng,Zhihua; Zheng,Zhihua; Zheng,Zhihua; Zheng,Zhihua; Yang,Weibang; Yang,Weibang; Yang,Weibang; Yang,Weibang; Yang,Weibang; Yang,Weibang; Yang,Weibang; Yang,Weibang; Yang,Weibang; Yang,Weibang; Yang,Weibang; Yang,Weibang; Zhuo,Wenfeng; Zhuo,Wenfeng; Zhuo,Wenfeng; Zhuo,Wenfeng; Zhuo,Wenfeng; Zhuo,Wenfeng; Zhuo,Wenfeng; Zhuo,Wenfeng; Zhuo,Wenfeng; Zhuo,Wenfeng; Zhuo,Wenfeng; Zhuo,Wenfeng; Yang,Sijia; Yang,Sijia; Yang,Sijia; Yang,Sijia; Yang,Sijia; Yang,Sijia; Yang,Sijia; Yang,Sijia; Yang,Sijia; Yang,Sijia; Yang,Sijia; Yang,Sijia; Cai,Diankui; Cai,Diankui; Cai,Diankui; Cai,Diankui; Cai,Diankui; Cai,Diankui; Cai,Diankui; Cai,Diankui; Cai,Diankui; Cai,Diankui; Cai,Diankui; Cai,Diankui; Duan,Jinxin; Duan,Jinxin; Duan,Jinxin; Duan,Jinxin; Duan,Jinxin; Duan,Jinxin; Duan,Jinxin; Duan,Jinxin; Duan,Jinxin; Duan,Jinxin; Duan,Jinxin; Duan,Jinxin; Liu,Peiqing; Liu,Peiqing; Liu,Peiqing; Liu,Peiqing; Liu,Peiqing; Liu,Peiqing; Liu,Peiqing; Liu,Peiqing; Liu,Peiqing; Liu,Peiqing; Liu,Peiqing; Liu,Peiqing; Min,Jun; Min,Jun; Min,Jun; Min,Jun; Min,Jun; Min,Jun; Min,Jun; Min,Jun; Min,Jun; Min,Jun; Min,Jun; Min,Jun; Wei,Jinxing; Wei,Jinxing; Wei,Jinxing; Wei,Jinxing; Wei,Jinxing; Wei,Jinxing; Wei,Jinxing; Wei,Jinxing; Wei,Jinxing; Wei,Jinxing; Wei,Jinxing; Wei,Jinxing

doi:10.3892/ijo.2024.5646

RPL9 acts as an oncogene by shuttling miRNAs through exosomes in human hepatocellular carcinoma cells

Authors:
- Ang Li
- Jiyan Xie
- Lihong Lv
- Zhihua Zheng
- Weibang Yang
- Wenfeng Zhuo
- Sijia Yang
- Diankui Cai
- Jinxin Duan
- Peiqing Liu
- Jun Min
- Jinxing Wei
View Affiliations

Affiliations: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat‑sen Memorial Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China, Department of Gastrointestinal Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China, Clinical Trial Institution of Pharmaceuticals, Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangdong Province Engineering Laboratory for Druggability and New Drug Evaluation, School of Pharmaceutical Sciences, Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China, Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, P.R. China, Department of Hepatobiliary Surgery, Fifth Affiliated Hospital, Sun Yat‑sen University, Zhuhai, Guangdong 528406, P.R. China, Department of Hepatobiliary Surgery, Sun Yat‑sen Memorial Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China
Published online on: April 18, 2024 https://doi.org/10.3892/ijo.2024.5646
Article Number: 58
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The exosomal pathway is an essential mechanism that regulates the abnormal content of microRNAs (miRNAs) in hepatocellular carcinoma (HCC). The directional transport of miRNAs requires the assistance of RNA‑binding proteins (RBPs). The present study found that RBPs participate in the regulation of miRNA content through the exosomal pathway in HCC cells. First, differential protein expression profiles in the serum exosomes of patients with HCC and benign liver disease were detected using mass spectrometry. The results revealed that ribosomal protein L9 (RPL9) was highly expressed in serum exosomes of patients with HCC. In addition, the downregulation of RPL9 markedly suppressed the proliferation, migration and invasion of HCC cells and reduced the biological activity of HCC‑derived exosomes. In addition, using miRNA microarrays, the changes in exosomal miRNA profiles in HCC cells caused by RPL9 knockdown were examined. miR‑24‑3p and miR‑185‑5p were most differentially expressed, as verified by reverse transcription‑quantitative PCR. Additionally, using RNA immunoprecipitation, it was found that RPL9 was directly bound to the two miRNAs and immunofluorescence assays confirmed that RPL9 was able to carry miRNAs into recipient cells via exosomes. Overexpression of miR‑24‑3p in cells increased the accumulation of miR‑24‑3p in exosomes and simultaneously upregulated RPL9. Excessive expression of miR‑24‑3p in exosomes also increased their bioactivity. Exosome‑mediated miRNA regulation and transfer require the involvement of RBPs. RPL9 functions as an oncogene, can directly bind to specific miRNAs and can be co‑transported to receptor cells through exosomes, thereby exerting its biological functions. These findings provide a novel approach for modulating miRNA profiles in HCC.